Moclobemid AL
Moclobemid AL Uses, Dosage, Side Effects, Food Interaction and all others data.
A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs). Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants [A3901].
A selective, reversible inhibitor of monoamine oxidase (MAO) which increases the . Besides its presence in sympathetic nerves, there is an abundant evidence that MAO-A is localized in noradrenergic neurons in the locus coeruleus and MAO-B is closely associated with serotonergic neurons of the raphe nucleus .
| Trade Name | Moclobemid AL |
| Generic | Moclobemide |
| Moclobemide Other Names | Moclobemid, Moclobemida, Moclobemide, Moclobemidum |
| Type | |
| Formula | C13H17ClN2O2 |
| Weight | Average: 268.739 Monoisotopic: 268.097855505 |
| Protein binding | Approximately 50% (primarily to albumin) |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Germany |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Moclobemid AL is a monoamine oxidase inhibitor used in the treatment of major depressive disorder and bipolar disorder.
For the treatment of major depressive disorder and bipolar disorder .
Moclobemid AL is also used to associated treatment for these conditions: Major Depressive Disorder (MDD)
How Moclobemid AL works
The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms .
Toxicity
LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures . The effects of moclobemide alone in overdose are negligible, even with high volume ingestion. However, moclobemide overdose with a serotonergic agent (even in small, therapeutic doses) can cause severe serotonin toxicity. The elimination half-life is prolonged by two to four times in overdose, compared with that found in healthy volunteers given therapeutic doses .
Food Interaction
- Avoid excessive or chronic alcohol consumption.
- Avoid tyramine-containing foods and supplements. Avoid excess consumption (
- Take after a meal.
Volume of Distribution
1-1.5 L/Kg
Elimination Route
Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first-pass metabolism reduces bioavailability to about 56% following administration of one dose, but increases to 90% with steady-state dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 0.3 - 1 hours following oral administration with a terminal half-life of 1.6h .
Half Life
1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted
Clearance
Clearance of 30-78 L/h , mainly excreted in urine.
Elimination Route
Moclobemid AL is almost completely renally excreted .
Innovators Monograph
You find simplified version here Moclobemid AL
